Orexigen Therapeutics (OREX) 7.36 $OREX Orexigen:

New Post Public Reply Private Reply Replies (0) Message Board

Apr 26, 2015 at 5:20 PM

Orexigen Therapeutics (OREX) 7.36 $OREX

Orexigen: Contrave Sales Pop, Equity Response Muted
Spencer Osborne - at Seeking Alpha - Fri Apr 24, 6:39PM CDT

OREX: 7.36 (-0.08), ACT: 295.41 (-2.95), VVUS: 2.46 (-0.04), ARNA: 4.49 (+0.05)

Arena: Belviq Scripts Pop, Recover From Previous Dip
Spencer Osborne - at Seeking Alpha - Fri Apr 24, 6:26PM CDT

OREX: 7.36 (-0.08), NVO: 56.65 (+0.44), ARNA: 4.49 (+0.05)

Orexigen Has Contrave Recapturing Early-Year Form, But Needs European Launch
Clinically Sound Investor - at Seeking Alpha - Fri Apr 24, 6:17PM CDT

OREX: 7.36 (-0.08), VVUS: 2.46 (-0.04), ARNA: 4.49 (+0.05)

Seeking Alpha's Biotech Weekly: Gilead Isn't Perfect, Biogen-Bass, Spring Fever, And More
SA Editor Mike Taylor - Seeking Alpha - Fri Apr 24, 3:00PM CDT
Every Friday, Seeking Alpha's Biotech Weekly highlights the editors' picks of the week's Seeking Alpha analysis, as well as a review of the top Breaking News stories. This week, contributors grappled with deals real and imagined, industry competition...
BIIB: 401.71 (-28.57), VRTX: 133.20 (-2.62), PRGO: 192.89 (-8.74), PFE: 35.27 (-0.09), CLDN: 13.68 (-0.26), MYL: 76.06 (+2.37), OREX: 7.36 (-0.08), JNJ: 101.08 (+0.62), NVO: 56.65 (+0.44), TNXP: 6.52 (-0.15), ALNY: 119.01 (+0.29), GILD: 103.69 (-1.52), SGEN: 37.14 (-0.36), ACHN: 10.06 (+0.06), MRK: 57.60 (+0.09), GALE: 1.45 (+0.02), JUNO: 56.66 (-1.06), SNY: 51.75 (-0.01), NBY: 0.63 (unch), XLRN: 33.29 (-0.95)

Biotech Equity Movers and Shakers -- Orexigen Therapeutics, Geron, Exelixis, XOMA Corp., and BioLine RX
PR Newswire - Fri Apr 24, 7:40AM CDT
Editor Note: For more information about this release, please scroll to bottom.
OREX: 7.36 (-0.08), GERN: 4.30 (-0.03), BLRX: 2.10 (-0.02), XOMA: 3.60 (-0.02), EXEL: 3.08 (-0.02)

Orexigen Investors Can Get Litigation Insight From Vivus
Spencer Osborne - at Seeking Alpha - Fri Apr 24, 7:29AM CDT

OREX: 7.36 (-0.08), ACT: 295.41 (-2.95), VVUS: 2.46 (-0.04)

Arena Pharmaceuticals Inc.'s Plan to Win the Obesity Drug War
Brian Orelli, The Motley Fool - Motley Fool - Fri Apr 24, 7:10AM CDT
Considering the number of obese Americans -- 35% of the entire U.S. adult population, according to the Centers for Disease Control and Prevention -- obesity-drug makers haven't come close to reaching their potential. Arena Pharmaceuticals reported...
OREX: 7.36 (-0.08), VVUS: 2.46 (-0.04), ARNA: 4.49 (+0.05)

Orexigen's Obesity Drug Contrave Faces Generic Threat - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 23, 5:37PM CDT
Orexigen (OREX) and partner Takeda received a Paragraph IV certification from Actavis, which is looking to get its generic version of Contrave approved in the U.S.
OREX: 7.36 (-0.08), ACT: 295.41 (-2.95), ARNA: 4.49 (+0.05)

TRADING ALERT: The Rosen Law Firm Reminds Orexigen Therapeutics, Inc. Investors of the Important May 11, 2015 Deadline in the Class Action
Business Wire - Thu Apr 23, 4:44PM CDT
The Rosen Law Firm, a global investor rights firm, reminds purchasers of the securities of Orexigen Therapeutics, Inc. (NASDAQ:OREX) from March 3, 2015 through March 5, 2015 of the important May 11, 2015 lead plaintiff deadline in the class action. The lawsuit seeks to recover investors' losses under the federal securities laws.
OREX: 7.36 (-0.08)

Orexigen - Contrave Sales Outpace Competition, But Are Still Not Enough
Spencer Osborne - at Seeking Alpha - Thu Apr 23, 7:32AM CDT

OREX: 7.36 (-0.08), ACT: 295.41 (-2.95), NVO: 56.65 (+0.44), VVUS: 2.46 (-0.04), ARNA: 4.49 (+0.05)

What Novo Nordisk's Entry Into The Obesity Space Means To The Sector
Spencer Osborne - at Seeking Alpha - Thu Apr 23, 7:06AM CDT

OREX: 7.36 (-0.08), NVO: 56.65 (+0.44), VVUS: 2.46 (-0.04), ARNA: 4.49 (+0.05)

Arena - Belviq Scripts Down: Competition, Or Lack Of Commitment From Partner Eisai?
Spencer Osborne - at Seeking Alpha - Thu Apr 23, 7:04AM CDT

OREX: 7.36 (-0.08), ARNA: 4.49 (+0.05)

Today's Dead Cat Bounce Stock: Orexigen Therapeutics (OREX)
at The Street - Wed Apr 22, 3:12PM CDT
Trade-Ideas LLC identified Orexigen Therapeutics (OREX) as a "dead cat bounce" (down big yesterday but up big today) candidate
OREX: 7.36 (-0.08)

Orexigen Faces Generic Challenge For Anti-Obesity Drug
Spencer Osborne - at Seeking Alpha - Wed Apr 22, 11:24AM CDT

OREX: 7.36 (-0.08), ACT: 295.41 (-2.95), VVUS: 2.46 (-0.04)

Novo's obesity drug will cost U.S. patients over $1,000 per month
Seeking Alpha - at Seeking Alpha - Wed Apr 22, 9:52AM CDT

OREX: 7.36 (-0.08), NVO: 56.65 (+0.44), VVUS: 2.46 (-0.04), ARNA: 4.49 (+0.05)

Orexigen Announces Receipt of Paragraph IV Certification Notice
PR Newswire - Wed Apr 22, 6:30AM CDT
Orexigen Therapeutics, Inc. (NASDAQ: OREX) today announced that Orexigen and North American partner Takeda Pharmaceuticals have received notification of a Paragraph IV certification for certain patents for Contrave® (naltrexone HCl and bupropion HCl extended release) which are listed in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations, or the Orange Book. The certification resulted from the filing by Actavis Laboratories FL, Inc. of an Abbreviated New Drug Application (ANDA) challenging such patents for Contrave.
OREX: 7.36 (-0.08)

SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notify Investors of Class Action Involving Orexigen Therapeutics, Inc. and a Lead Plaintiff Deadline of May 11, 2015
Business Wire - Tue Apr 21, 9:39AM CDT
The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of New York on behalf of investors who purchased Orexigen Therapeutics, Inc. ("Orexigen" or the "Company"

(NASDAQ:OREX) securities between March 3, 2015 and March 5, 2015.
OREX: 7.36 (-0.08)

3 Promising Small-Caps Under $10 You Can Buy Right Now
Dan Caplinger, Selena Maranjian, and Todd Campbell, The Motley Fool - Motley Fool - Tue Apr 21, 8:06AM CDT
The healthcare arena is a hotbed of interesting small-cap plays, including Orexigen Therapeutics, the maker of the obesity drug Contrave. Image: Orexigen Therapeutics. Many investors are afraid of investing in small-cap stocks, believing that the...
MBI: 9.10 (+0.04), OREX: 7.36 (-0.08), ARNA: 4.49 (+0.05)

Glancy Binkow & Goldberg LLP Reminds Investors of the Lead Plaintiff Deadline in the Class Action Lawsuit Against Orexigen Therapeutics, Inc.
Business Wire - Mon Apr 20, 9:54AM CDT
Glancy Binkow & Goldberg LLP reminds investors in Orexigen Therapeutics, Inc. ("Orexigen" or the "Company"

(NASDAQ: OREX) who purchased the Company's securities between March 3 and March 5, 2015, inclusive (the "Class Period"

of the May 11, 2015 deadline to file a motion to be appointed as lead plaintiff in the shareholder lawsuit.
OREX: 7.36 (-0.08)

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Orexigen Therapeutics, Inc. of Pendency of Class Action Lawsuit and a Lead Plaintiff Deadline of May 11, 2015 - OREX
PR Newswire - Wed Apr 15, 9:17AM CDT
The following statement is being issued by Levi & Korsinsky, LLP:
OREX: 7.36 (-0.08)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Ardelyx Securities Fraud Suit: Key Investor Moves

Fraud Allegations: Ardelyx Under the Microscope Looks like Ardelyx has found itself neck-deep in trouble, facing a class action lawsuit over alleged securities fraud. This isn't just a storm in a teacup. We're talking about accusations of false and misleading statements tied to their commercial performance—statements that might have left investors holding the bag with...

Boliden's Q3 2026 Results: What's on the Horizon?

Boliden Ready to Reveal Q3 Numbers Mark it down, folks. Thursday, October 29, 2026, is the day when Boliden's big wigs will step up to the plate and lay their cards on the table about the company's performance over the last quarter. If you've got any skin in this mining powerhouse, you'll want a front-row seat—or at least a virtual one if you're dialing in from...

Steel Dynamics Gears Up for Q3 2026 Earnings Update

Steel Dynamics Preps for Key Earnings Report Folks, we're staring down the barrel of another quarterly earnings report from Steel Dynamics, Inc., and you can bet this one is gonna have plenty of eyes glued. October 19th, 2026, that's when they'll peel back the curtain on how they fared in Q3. Now, buckle up, because this isn't just a numbers game—it’s a snapshot of...

CME Group Unveils First Baseball Futures Market

A New Pitch in the Financial Ballpark Alright, listen up: CME Group is stepping up to the plate with a game-changer. They’re rolling out the world’s first baseball futures, launching October 12, assuming regulators give the green light. Now, this isn’t just some novelty act; it’s based on the solid groundwork of their FutureSports Performance Indexes (CME FSPI),...

Morphe’s Auction Hits High Notes with Fine Jewelry

Luxurious Gems Steal the Spotlight When the gavel dropped at Morphy's Fine Jewelry & Watches Auction, it set the stage for a spectacular showcase of opulent treasures. The event, highlighting 632 lots and tallying over $1.8 million in sales, left bidders buzzing in anticipation of their next chance to snag a slice of elegance. Bvlgari's Serpentine Charm In the spotlight...

Strategic Move: Chimney Collective Teams with Four Winds

A Partnership Fueled by Legacy and Growth In the world of brick, mortar, and flue, a big play just unfolded. Chimney Collective, flexing its investment muscle, has hitched its wagon to Four Winds Chimney, a company that's carved out quite a niche in New York's chimney scene. We're not talking about a corporate takeover here; this is about putting money where growth and...

Helio Genomics Shakes Up Liver Cancer Detection Strategy

Rethinking Liver Cancer Detection with HelioLiver Sometimes you stumble upon a tech piece that might genuinely shake up the game. Helio Genomics just poured some serious intel at the San Antonio Liver Cancer Symposium, showcasing how their HelioLiver Dx might outgun traditional scans in sniffing out hepatocellular carcinoma (HCC). They threw down four studies revealing...

DIFF Eyewear Opens First Flagship Store in Charleston

DIFF Eyewear: From Clicks to Bricks in Charleston Here's a tale of a brand shaking things up, jumping from the digital stratosphere right into solid ground. DIFF Eyewear has officially planted its flag in Charleston, SC, marking a bold transition from being an exclusively online player to real-world retail. October 10th rang in their first brick-and-mortar store on...

Bill Evans Enhances Gateway's Wealth Management Expertise

Welcome Aboard, Bill Evans Some days the financial world throws a gem your way, something worth more than a rat-race racehorse in a shattered stock rally. Meet Bill Evans, a seasoned professional stepping into the vibrant arena of Gateway Financial Partners. He’s put in 29 years around the investment block, and now he’s parking himself in Glastonbury, Connecticut, set...

Hexaware Teams with Anthropic for Game-Changing AI Move

A Bold AI Partnership on the Horizon Mutual back-slapping or a deal with authentic grit? Hexaware’s latest tango with Anthropic might just be the jolt enterprises need. Announced under the flickering fluorescent lights of Mumbai, London, and Iselin, Hexaware’s multi-year partnership with Anthropic thrusts Claude, their razor-sharp AI, right into the mix of...